MYGN: Is Myriad Genetics, Inc. Halal?
Myriad Genetics, Inc.
$3.05
Price as of Aug 25, 2026
Market Cap: 288.1M
Compliance Status
Not Halal
Screened on Sep 8, 2026 · AAOIFI Standard 21
Non-Compliant
Is Myriad Genetics, Inc. (MYGN) halal? Not Halal. Based on AAOIFI screening, Myriad Genetics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).
Quote this verdict
HalalScreener rates Myriad Genetics, Inc. (MYGN) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 8, 2026. Source: https://halalscreener.app/en/stock/MYGN
Business activity
What the company sells is permissible.
Company debt
Over the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
Most scholars advise not holding MYGN
It does not pass AAOIFI Shariah screening.
See halal alternatives from the same sector further down this page
Get an email if MYGN's halal status changes
We re-screen Myriad Genetics, Inc. daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Sector: Healthcare · Industry: Medical - Diagnostics & Research
Why this does not pass
- Interest-bearing debt is 40.1% of market cap, over the 30% AAOIFI limit.
- Interest-bearing deposits are over the 30% limit.
Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.
Shariah Compliance Status
See which ratio caused the failure.
See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.
AI Compliance Insight
PROInstitutional-grade Shariah analysis
See why MYGN is rated Not Halal with institutional-grade analysis
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
Compliance History
Not Halalnow
since Aug 2026
Doubtful
until the change above
Halal
until the change above
Not Halal
until the change above
Halal
until the change above
Doubtful
until the change above
Not Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
Halal Alternatives in Healthcare
This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:
More Healthcare Stocks
Track MYGN and 8,200+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Frequently Asked Questions
Is Myriad Genetics, Inc. (MYGN) halal to invest in?
Why did Myriad Genetics, Inc. get a F compliance rating?
What could change Myriad Genetics, Inc.'s Shariah verdict?
How often is Myriad Genetics, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.